About this Research Topic
Respiratory infectious diseases, such as viral pneumonia, pose a serious threat to global public health. These diseases spread rapidly and widely, potentially causing severe complications such as respiratory failure and multi-organ failure, which seriously endanger the life and health of patients. The development of safe and effective drug treatment for respiratory infectious diseases and related complications in other systems is of great significance. Current trends in drug development for respiratory infectious diseases are increasingly focusing on areas such as antimicrobial drugs, immunomodulatory drugs, vaccine production and optimization, and biotherapeutic drug development. In particular, novel vaccines and broad-spectrum antiviral drugs for the pathogens have garnered significant attention, especially in light of the COVID-19 pandemic.
In this research topic, we seek to explore novel trends and strategies, gathering insights into developing drug therapies for respiratory infectious diseases, exemplified by pneumonia. This includes novel drug treatment and repurposed drug therapy that target the specific pathogens and immune system, as well as the related molecular mechanism, aiming to effectively address the recurrence of previous respiratory infections and the emergence of new epidemics and reduce the incidence of complications, and improve the quality of survival of patients.
Authors are welcome to discuss drug development for respiratory infectious diseases, particularly pneumonia, as well as related complications in other systems, including but not limited to the following sub-topics:
1. Drug design and synthesis
2. Screening and validation of drug targets
3. Repurposed drugs
4. Mechanisms
5. Pre-market and post-approval clinical evaluation of drugs for respiratory infectious diseases
6. Novel trends in drug development for respiratory infectious diseases
7. Current challenges in drug discovery for respiratory diseases
In this research topic, we seek to explore novel trends and strategies, gathering insights into developing drug therapies for respiratory infectious diseases, exemplified by pneumonia. This includes novel drug treatment and repurposed drug therapy that target the specific pathogens and immune system, as well as the related molecular mechanism, aiming to effectively address the recurrence of previous respiratory infections and the emergence of new epidemics and reduce the incidence of complications, and improve the quality of survival of patients.
Authors are welcome to discuss drug development for respiratory infectious diseases, particularly pneumonia, as well as related complications in other systems, including but not limited to the following sub-topics:
1. Drug design and synthesis
2. Screening and validation of drug targets
3. Repurposed drugs
4. Mechanisms
5. Pre-market and post-approval clinical evaluation of drugs for respiratory infectious diseases
6. Novel trends in drug development for respiratory infectious diseases
7. Current challenges in drug discovery for respiratory diseases
Keywords: systemic complications, drug, respiratory infections, pneumonia
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
